In short. Melasma, active acne, recent isotretinoin, a keloid tendency and skin that cannot take downtime are reasons to decline both. Declining protects the skin.
Key points
- An assessment that ends in no treatment protects the skin from a result that would have been difficult or impossible to correct.
- That is the same reasoning as declining an operation for a patient who is not fit for it, and it should be explained in those terms rather than as a refusal.
Every comparison of two treatments raises a third option that is discussed far less often: neither. For a group of patients, the correct answer to the question in this site’s title is that both routes are wrong for now, and reaching that answer is a successful assessment rather than a failed one.
Melasma, and pigment disorders generally
Melasma is a pigment disorder in which the skin produces excess pigment, and inflammation is one of the things that drives it. Both routes in this comparison create inflammation by design, which is why treating melasma with either can make it worse rather than better, and why a flare can persist after the treatment that caused it. A patient who comes asking for resurfacing of what is actually melasma needs the diagnosis first, and the treatment of that diagnosis is a different conversation.
Active acne, infection and a damaged barrier
Skin that is actively inflamed is skin already under stress, and adding a controlled injury to it does not produce a controlled result. Active acne is usually brought under control first. Any current infection in the area is treated before treatment is considered. A barrier damaged by over-treatment, by a reaction or by a long course of irritating products is allowed to recover, because treating through it is how a temporary problem becomes a lasting one.
Declining protects the result, not just the patient
An assessment that ends in no treatment protects the skin from a result that would have been difficult or impossible to correct. That is the same reasoning as declining an operation for a patient who is not fit for it, and it should be explained in those terms rather than as a refusal.
Recent systemic retinoid treatment
Patients who have recently finished a course of systemic retinoid treatment for acne are usually asked to wait before resurfacing is considered, because the skin’s healing behaviour during and shortly after that treatment is not the behaviour the plan was designed around. How long the wait should be is a clinical judgement depending on the dose, the duration and the individual, and it is made at an examination.
A tendency for scars to thicken
A patient whose scars have thickened or spread beyond the original injury carries a higher risk from any treatment that creates a wound, including the healing phase of resurfacing. That finding does not always rule out both routes, but it changes what can safely be attempted and how conservative the plan should be. It is a history question, and it is one of the reasons the history is taken before the skin is examined.
The refusals, in one list
- A pigment disorder such as melasma, which either route can worsen rather than improve.
- Active acne or a current skin infection in the area, which is treated first.
- A recent course of systemic retinoid treatment, a tendency for scars to thicken, or a healing period that cannot be protected from sun.
None of these findings means that nothing can be done. Each means that what can be done is different from what was asked for, and that the difference is worth understanding before any treatment rather than after it.
Frequently asked questions
Why would a clinic decline to treat me at all?
Because some findings turn a treatment that usually helps into one that is likely to cause harm. Active inflammation, a pigment disorder such as melasma, recent systemic retinoid treatment and a tendency for scars to thicken all sit in that group. Declining is a clinical decision about risk, not a judgement about the patient.
Is it worth treating melasma with resurfacing?
In most cases it is not, because the inflammation of treatment is one of the things that drives melasma to worsen. A pigment disorder is assessed and managed as its own condition, and a resurfacing plan is made around it rather than through it. This is a common point at which a plan that sounded straightforward becomes a different plan.
What happens instead if both routes are declined?
The condition or the finding blocking treatment is addressed first, and a different route to the original complaint is considered. That may be a medical treatment, a procedure that does not involve resurfacing, or simply waiting until the skin is in a state where treatment is reasonable again.
Risks & Limitations
- No result can be guaranteed, and healing times vary between people.
- Pigment change after an ablative treatment may fade only partly, or not at all.
- Heat delivered below the skin can injure the fat beneath it, and that change is lasting.
- Neither route removes a scar or tightens loose skin, and further treatment may be needed.
When to Seek Care
- Blistering, spreading redness or worsening pain in a treated area.
- Fever, or discharge or warmth from skin that is healing.
- A cold sore outbreak after treatment in a patient with a history of them.
- Any new or changing mark on treated skin, which should be examined rather than observed.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — skin resurfacing and safety guidance
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews on resurfacing and scarring
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.